The current landscape for the treatment of mitochondrial disorders
- PMID: 29502956
- DOI: 10.1016/j.jgg.2017.11.008
The current landscape for the treatment of mitochondrial disorders
Abstract
The mitochondrial organelle is crucial to the energy metabolism of the eukaryotic cell. Defects in mitochondrial function lie at the core of a wide range of disorders, including both rare primary mitochondrial disorders and more common conditions such as Parkinson's disease and diabetes. Inherited defects in mitochondrial function can be found in both the nuclear genome and the mitochondrial genome, with the latter creating unique challenges in the treatment and understanding of disease passed on through the mitochondrial genome. In this review, we will describe the limited treatment regimens currently used to alleviate primary mitochondrial disorders, as well as the potential for emerging technologies (in particular, those involving direct manipulation of the mitochondrial genome) to more decisively treat this class of disease. We will also emphasize the critical parallels between primary mitochondrial disorders and more common ailments such as cancer and diabetes.
Keywords: Genetic disorders; Mitochondrial disease; Therapy.
Copyright © 2018. Published by Elsevier Ltd.
Similar articles
-
Toward a therapy for mitochondrial disease.Biochem Soc Trans. 2016 Oct 15;44(5):1483-1490. doi: 10.1042/BST20160085. Biochem Soc Trans. 2016. PMID: 27911730 Free PMC article. Review.
-
The contribution of mitochondria to common disorders.Mol Genet Metab. 2003 Sep-Oct;80(1-2):11-26. doi: 10.1016/j.ymgme.2003.08.009. Mol Genet Metab. 2003. PMID: 14567954 Review.
-
Mitochondrial Diseases: Hope for the Future.Cell. 2020 Apr 2;181(1):168-188. doi: 10.1016/j.cell.2020.02.051. Epub 2020 Mar 26. Cell. 2020. PMID: 32220313 Review.
-
Mitochondrial genetic medicine.Nat Genet. 2018 Dec;50(12):1642-1649. doi: 10.1038/s41588-018-0264-z. Epub 2018 Oct 29. Nat Genet. 2018. PMID: 30374071 Review.
-
GENETICS. Mitochondrial-nuclear DNA mismatch matters.Science. 2015 Sep 25;349(6255):1449-50. doi: 10.1126/science.aac5271. Science. 2015. PMID: 26404813 Free PMC article. No abstract available.
Cited by
-
Mitochondrial Chronic Progressive External Ophthalmoplegia.Brain Sci. 2024 Jan 27;14(2):135. doi: 10.3390/brainsci14020135. Brain Sci. 2024. PMID: 38391710 Free PMC article. Review.
-
Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice.Mol Ther Methods Clin Dev. 2020 May 22;18:84-97. doi: 10.1016/j.omtm.2020.05.021. eCollection 2020 Sep 11. Mol Ther Methods Clin Dev. 2020. PMID: 32995353 Free PMC article.
-
DNA-editing enzymes as potential treatments for heteroplasmic mtDNA diseases.J Intern Med. 2020 Jun;287(6):685-697. doi: 10.1111/joim.13055. Epub 2020 Apr 27. J Intern Med. 2020. PMID: 32176378 Free PMC article. Review.
-
Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46-/- mice.Hum Mol Genet. 2020 Mar 13;29(4):649-661. doi: 10.1093/hmg/ddz277. Hum Mol Genet. 2020. PMID: 31943007 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical